CN105968190A - Cd30免疫原多肽及其用途 - Google Patents
Cd30免疫原多肽及其用途 Download PDFInfo
- Publication number
- CN105968190A CN105968190A CN201610438243.2A CN201610438243A CN105968190A CN 105968190 A CN105968190 A CN 105968190A CN 201610438243 A CN201610438243 A CN 201610438243A CN 105968190 A CN105968190 A CN 105968190A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- cell
- immunogen
- application
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 55
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 54
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 54
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 title claims abstract description 24
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 title claims abstract description 24
- 230000002163 immunogen Effects 0.000 title claims abstract description 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 17
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 4
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 abstract description 8
- 230000004083 survival effect Effects 0.000 abstract description 6
- 230000002093 peripheral effect Effects 0.000 abstract description 5
- 229940022399 cancer vaccine Drugs 0.000 abstract description 4
- 238000002659 cell therapy Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 4
- 201000002341 thymus lymphoma Diseases 0.000 abstract description 4
- 210000000265 leukocyte Anatomy 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 238000011523 CAR-T cell immunotherapy Methods 0.000 abstract 1
- 230000006052 T cell proliferation Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000011282 treatment Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 229960000455 brentuximab vedotin Drugs 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 description 2
- 229960000214 pralatrexate Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 229960003452 romidepsin Drugs 0.000 description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 2
- 108010091666 romidepsin Proteins 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- MIPWEZAIMPYQST-FXQIFTODSA-N Ala-Cys-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O MIPWEZAIMPYQST-FXQIFTODSA-N 0.000 description 1
- DGFGDPVSDQPANQ-XGEHTFHBSA-N Arg-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCN=C(N)N)N)O DGFGDPVSDQPANQ-XGEHTFHBSA-N 0.000 description 1
- CNBIWSCSSCAINS-UFYCRDLUSA-N Arg-Tyr-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CNBIWSCSSCAINS-UFYCRDLUSA-N 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 229940126161 DNA alkylating agent Drugs 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- IPHGBVYWRKCGKG-FXQIFTODSA-N Gln-Cys-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O IPHGBVYWRKCGKG-FXQIFTODSA-N 0.000 description 1
- PBYFVIQRFLNQCO-GUBZILKMSA-N Gln-Pro-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O PBYFVIQRFLNQCO-GUBZILKMSA-N 0.000 description 1
- UTKUTMJSWKKHEM-WDSKDSINSA-N Glu-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O UTKUTMJSWKKHEM-WDSKDSINSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- BJPQKNHZHUCQNQ-SRVKXCTJSA-N Met-Pro-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCSC)N BJPQKNHZHUCQNQ-SRVKXCTJSA-N 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- HFZNNDWPHBRNPV-KZVJFYERSA-N Pro-Ala-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HFZNNDWPHBRNPV-KZVJFYERSA-N 0.000 description 1
- FIODMZKLZFLYQP-GUBZILKMSA-N Pro-Val-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FIODMZKLZFLYQP-GUBZILKMSA-N 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- BSCBBPKDVOZICB-KKUMJFAQSA-N Tyr-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BSCBBPKDVOZICB-KKUMJFAQSA-N 0.000 description 1
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000005284 basis set Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000001350 reed-sternberg cell Anatomy 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种CD30免疫原多肽，属于抗癌疫苗领域。具体涉及用作抗癌疫苗的CD30免疫原的优化多肽，增强T细胞免疫应答。该氨基酸序列为全新的序列，在制备用于治疗肿瘤药物中的应用。尤其在制备用于肿瘤免疫细胞，增强T细胞免疫应答药物中的应用，以及在制备用于CAR‑T细胞免疫治疗的应用。本发明的有益效果在于为全新的序列，可用于肿瘤免疫细胞技术中的免疫原，能（1）促进T细胞增殖，（2）抑制小鼠外周白细胞表面CD30表达，（3）能与T细胞表面的MHC有效的特异性结合，（4）能提高胸腺淋巴瘤小鼠生存率。作为细胞疗法的靶标分子，应用于CAR‑T等细胞疗法。
Description
技术领域
本发明是有关抗癌疫苗领域。具体来说，本发明涉及用作抗癌疫苗的CD30免疫原的优化多肽，增强T细胞免疫应答。
背景技术
CD30(TNFRSF8)是最初发现于何杰金氏病(Hodgkin’s disease)中的里丝氏细胞(Reed Sternberg cell)上的跨膜糖蛋白。近年发现活化T细胞高表达该分子。尤其是，CD30可表达于多种恶性淋巴系统疾病，如霍奇金淋巴瘤(HL)、间变性大细胞性淋巴瘤(ALCL)、外周T细胞淋巴瘤(PTCL)、成人T细胞性淋巴瘤(ATL)等，其中以T细胞淋巴瘤占大多数，如ALCL肿瘤细胞中CD30表达可达100％。
相对于近年来B细胞淋巴瘤治疗领域中的异彩纷呈，如多种化疗方案，干细胞移植，抗CD20单抗、硼替佐米、来那度胺、Ibrutinib等新型药物不断优化着治疗格局，外周T细胞淋巴瘤的治疗则进展不大。主要方案以化疗为主要治疗手段，辅以放疗。目前，靶向治疗复发/难治性CD30+T细胞淋巴瘤成为热门话题，已有诸多单药治疗研究见诸报道。有阿仑单抗、硼替佐米、brentuximabvedotin(sALCL)、环抱素(AITL)、吉西他滨、普拉曲沙、罗米地辛。食品药品监督管理局(FDA)批准的药物有普拉曲沙、罗米地辛、brentuximabvedotin(对ALCL)，有效率分别为29％、25％、86％。
肿瘤细胞免疫治疗是一种新兴的、具有显著疗效的肿瘤治疗模式，是一种自身免疫抗癌的新型治疗方法。它是运用生物技术和生物制剂对从病人体内采集的免疫细胞进行体外培养和扩增后回输到病人体内的方法，来激发，增强机体自身免疫功能，从而达到治疗肿瘤的目的。肿瘤细胞免疫疗法是继手术、放疗和化疗之后的第四大肿瘤治疗技术。
CD30可以作为肿瘤疫苗的特异性免疫原。然而，CD30由595个氨基酸残基组成，分子量较大，较难得到纯度高的CD30。这样，不仅会给后期的特异性T细胞免疫带来困难，而且会导致患者的自身免疫。因此，本发明提供了一种特异性强，纯度较高的小分子多肽作为免疫原。
发明内容
发明目的
本发明提供一种CD30免疫原多肽，可用于肿瘤细胞免疫的免疫原，增强T细胞免疫应答，具有分子量小、特异性免疫原性强的特点。
技术方案
本发明的技术方案在于提供一种CD30免疫原多肽，序列为PVSPATMPVRYYQCEPQPQYLDEAGRCTACVAQEAARGDR(SEQ ID NO：1)。该氨基酸序列为全新的序列，在制备用于治疗肿瘤药物中的应用。尤其在制备用于肿瘤免疫细胞，增强T细胞免疫应答药物中的应用，以及在制备用于CAR-T细胞免疫治疗的应用。
有益效果
本发明的CD30免疫原多肽，为全新的序列，可用于肿瘤免疫细胞技术中的免疫原。有益效果在于(1)促进T细胞增殖，(2)抑制小鼠外周白细胞表面CD30表达，(3)能与T细胞表面的MHC有效的特异性结合，(4)能提高胸腺淋巴瘤小鼠生存率。作为细胞疗法的靶标分子，应用于CAR-T等细胞疗法。
具体实施方式
多肽由上海生工吉尔合成。
实施例1
用小鼠胸腺淋巴瘤模型检测CD30免疫原多肽的体内活力。
6-8w龄C57BL/6小鼠，小鼠随机分成4组，雌雄各半，每组10只。(1)空白组；(2)多肽低剂量组；(3)多肽中剂量组；(4)多肽高剂量组。腹腔注射DNA烷化剂N-甲基-N-亚硝基脲(MNU)诱导小鼠胸腺淋巴瘤，建立相应动物模型，在造模后的第1、7、14、21天，分别进行免疫。方案为：空白组加入相同体积的溶剂，实验组多肽设3个剂量：5、10、20mg/Kg，在肿瘤周围多点注射。28天后，观察小鼠存活数量，计算存活率。结果显示，多肽可有效提高荷瘤小鼠的生存率，其中，剂量为20mg/Kg组的小鼠生存率达到76.12％。
实施例2
应用竞争性受体-配体亲和法测试多肽与MHC的结合能力：
将多肽与HLA各型的结合能力由竞争性受体-配体亲和法判断。将固定浓度为50μmol/L的标记125I的多肽以及不同浓度(1-50μmol/L)的多肽加入反应体系(磷酸盐缓冲液和MHC，所述的MHC试剂盒购自上海泛柯生物科技有限公司，试剂盒内有HLA-A1、A2、A3、A11和A24)，在反应体系中形成两种复合物，即待测多肽MHC复合物和125I标记多肽复合物。待测多肽与125I标记多肽竞争与MHC的结合。用超过滤(产品型号Microcon 30，Amicon公司)分离游离多肽和多肽MHC复合物，然后测定多肽MHC复合物的125I放射量，将此放射量与没有竞争性抑制的多肽MHC复合物(没有加待测多肽的样本)的放射量比较，求待测多肽在抑制50％标记多肽与MHC结合时的浓度，即IC50。由此得到，多肽对HLA-A1、A2、A3、A11和A24的IC50值分别为5.28、4.13、7.58、4.74和6.01μmol/L，均符合阳性多肽的标准(≤10μM)。因此，多肽为具有有效结合能力的免疫原多肽。
实施例3
T淋巴细胞的增殖作用：无菌取小鼠脾脏，1640培养基清洗3次，5ml注射器芯研磨，200目筛网过滤，制成单细胞悬液，离心(1000r/min，5min)，弃上清，Tris-NH4CL破解红细胞，冰水浴静置3-5min，离心(1000r/min,5min)，弃上清，用无菌冷PBS洗涤细胞两次。最后加入10％小牛血清的RPMI 1640培养液(5ml)悬浮细胞，细胞计数，调整细胞浓度为5×106个/ml，于96孔培养板中培养。
实验设空白对照组、模型组(刀豆蛋白A，sigma公司购买)、多肽各剂量(5、10、20mg/ml)组。各组分别加入脾脏淋巴细胞悬液100μl/孔后，空白对照组加入1640培养液100μl，模型组加入ConA(终浓度为5μg/ml)，多肽各剂量组在加入不同浓度的多肽基础上加ConA(终浓度为5μg/ml)。37℃细胞培养箱静止培养48h，培养结束后每孔加入20μl MTT，继续培养4h，最后弃掉每孔所有溶液，每孔加入100μlDMSO，震荡，用酶标仪检测570nm处OD值，每孔设5个平行。
表1多肽对T淋巴细胞的增殖作用
*P<0.05，**P<0.01与模型组相比。
实验结果见表1，与模型组比较，多肽能促进小鼠脾脏淋巴细胞的增殖，在剂量为5～20mg/ml的范围呈现很好的剂量依赖关系。
实施例4
采用流式细胞技术测定免疫原多肽对免疫动物体内T细胞表面CD30表达的影响。6-8w龄C57BL/6小鼠，小鼠随机分成4组，每组10只。(1)空白组；(2)免疫原多肽低剂量组；(3)免疫原多肽中剂量组；(4)多肽高剂量组。在试验的第0、7、14天，分别进行免疫。方案为：空白组加入相同体积的溶剂，实验组多肽设3个剂量：5、10、20mg/Kg，在小鼠背部淋巴结附近多点注射。30天后，眼球取血0.8ml，肝素抗凝，将血离心后取血细胞层，用红细胞裂解液破解红细胞，洗去裂解的红细胞，再用荧光标记的CD30+-FITC(购自北京华泰昕生物医疗技术有限公司)孵育、固定后，进行流式细胞技术测定，评价免疫原多肽对CD30+T细胞的影响。
表2多肽对CD30抗体+T淋巴细胞的作用
*P<0.05，**P<0.01与空白组相比。
实验结果见表2，与空白组比较，多肽能抑制小鼠外周白细胞表面CD30表达，在剂量为5～20mg/Kg的范围呈现很好的剂量依赖关系。
SEQUENCE
LISTING
<110>
苏州普罗达生物科技有限公司
<120>
CD30免疫原多肽及其用途
<130>
<160>
1
<170>
PatentIn version 3.3
<210>
1
<211>
40
<212>
PRT
<213>
人工序列
<400>
1
Pro Val Ser
Pro Ala Thr Met Pro Val Arg Tyr Tyr Gln Cys Glu Pro
1
5
10
15
Gln Pro Gln
Tyr Leu Asp Glu Ala Gly Arg Cys Thr Ala Cys Val Ala
20
25
30
Gln Glu Ala
Ala Arg Gly Asp Arg
35
40
Claims (4)
1.一种CD30免疫原多肽，其特征在于：所述的多肽序列为SEQ ID NO：1。
2.根据权利要求1所述的多肽，其特征在于：在制备用于治疗肿瘤药物中的应用。
3.根据权利要求2所述的多肽，其特征在于：在制备用于肿瘤免疫细胞，增强T细胞免疫应答药物中的应用。
4.根据权利要求2所述的多肽，其特征在于：在制备用于CAR-T细胞免疫治疗的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610438243.2A CN105968190A (zh) | 2016-06-19 | 2016-06-19 | Cd30免疫原多肽及其用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610438243.2A CN105968190A (zh) | 2016-06-19 | 2016-06-19 | Cd30免疫原多肽及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105968190A true CN105968190A (zh) | 2016-09-28 |
Family
ID=57021901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610438243.2A Pending CN105968190A (zh) | 2016-06-19 | 2016-06-19 | Cd30免疫原多肽及其用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105968190A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103336131A (zh) * | 2013-06-25 | 2013-10-02 | 中国人民解放军海军医学研究所 | 可溶性cd30作为快速估算电离辐射剂量生物指标的应用 |
| CN104592392A (zh) * | 2015-01-21 | 2015-05-06 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体EpCAM×CD3的构建及应用 |
-
2016
- 2016-06-19 CN CN201610438243.2A patent/CN105968190A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103336131A (zh) * | 2013-06-25 | 2013-10-02 | 中国人民解放军海军医学研究所 | 可溶性cd30作为快速估算电离辐射剂量生物指标的应用 |
| CN104592392A (zh) * | 2015-01-21 | 2015-05-06 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体EpCAM×CD3的构建及应用 |
Non-Patent Citations (1)
| Title |
|---|
| 冯元怡等: "ConA刺激小鼠T淋巴细胞期事件研究", 《北京医科大学学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy | |
| Calzascia et al. | Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs | |
| CN108495649A (zh) | 治疗性抗癌新表位疫苗 | |
| CN107034235A (zh) | 联合靶向pd‑1及egfr的嵌合性抗原t细胞肿瘤免疫方法 | |
| EP3587440B1 (en) | Human pd-l1 high-protein-affinity peptide and use thereof | |
| van Elsas et al. | Host genetics and tumor environment determine the functional impact of neutrophils in mouse tumor models | |
| CN105753978A (zh) | 一种hla-a11限制性癌胚抗原来源的表位肽及用途 | |
| CN106222141A (zh) | Nk细胞培养液和细胞培养方法 | |
| JP6687246B2 (ja) | 改変型免疫細胞、改変型免疫細胞の製造方法、およびこれらの利用 | |
| Kohchi et al. | Utilization of macrophages in anticancer therapy: the macrophage network theory | |
| CN107849091A (zh) | 能够在人脂肪衍生的干细胞和肝细胞中抑制丙肝病毒复制的肽及其衍生物 | |
| CN106822861A (zh) | 抗原肽gpc3‑1和gpc3‑3在制备治疗肝癌药物中的应用 | |
| AU2019226021A1 (en) | Universal antigen presenting cells and uses thereof | |
| CN110559424B (zh) | 一种外膜蛋白在制备恶性肿瘤免疫治疗药物中的应用 | |
| CN105254744B (zh) | 多肽xzz-5的异源表达及其在增强cik细胞杀瘤活性中的应用 | |
| CN105968190A (zh) | Cd30免疫原多肽及其用途 | |
| CN105968188A (zh) | 一种关于cd30免疫原多肽及其用途 | |
| CN113980133B (zh) | 抗体及其在抗肿瘤中的应用 | |
| CN113956359B (zh) | 一种抗体及其在抗肿瘤中的应用 | |
| CN106084034A (zh) | 一种cd30免疫原多肽及其用途 | |
| CN106008695A (zh) | 一种关于cd19免疫原多肽及其用途 | |
| CN106366179A (zh) | 一种跨膜硫酸乙酰肝泰蛋白多糖1免疫激动剂多肽及其用途 | |
| CN106336456A (zh) | 一种cd33免疫原多肽及其用途 | |
| CN105906705A (zh) | 一种cd19免疫原多肽及其用途 | |
| CN105924513A (zh) | 一种紧密连接免疫原多肽及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160928 |
|
| WD01 | Invention patent application deemed withdrawn after publication |